Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Wakeling

Showing results (81-90 of 88) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 88 results.
Endocrine-Related Cancer|September 22, 2001
Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancerR I Nicholson, I R Hutcheson, M E Harper, et al.
Annals of the New York Academy of Sciences|July 4, 2002
Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancerR I Nicholson, I R Hutcheson, M E Harper, et al.
Breast Cancer Research and Treatment|January 1, 1996
Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genesR A McClelland, D L Manning, J M Gee, et al.
Endocrinology|September 10, 2003
The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitroJ M W Gee, M E Harper, I R Hutcheson, et al.
Cancer Research|September 18, 2001
Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancerJ F Robertson, R I Nicholson, N J Bundred, et al.
Archives of Disease in Childhood|May 1, 1996
Ionic control of beta cell function in nesidioblastosis. A possible therapeutic role for calcium channel blockadeK J Lindley, M J Dunne, C Kane, et al.
Endocrine-Related Cancer|August 23, 2005
Consensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signalling pathways and implications for future treatmentJ M W Gee, A Howell, W J Gullick, et al.
Journal of Molecular Endocrinology|September 29, 2012
Mutations in CUL7, OBSL1 and CCDC8 in 3-M syndrome lead to disordered growth factor signallingD Hanson, P G Murray, T Coulson, et al.
Pageof 9

Showing results (81-90 of 88) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 88 results.
Endocrine-Related Cancer|September 22, 2001
Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancerR I Nicholson, I R Hutcheson, M E Harper, et al.
Annals of the New York Academy of Sciences|July 4, 2002
Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancerR I Nicholson, I R Hutcheson, M E Harper, et al.
Breast Cancer Research and Treatment|January 1, 1996
Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genesR A McClelland, D L Manning, J M Gee, et al.
Endocrinology|September 10, 2003
The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitroJ M W Gee, M E Harper, I R Hutcheson, et al.
Cancer Research|September 18, 2001
Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancerJ F Robertson, R I Nicholson, N J Bundred, et al.
Archives of Disease in Childhood|May 1, 1996
Ionic control of beta cell function in nesidioblastosis. A possible therapeutic role for calcium channel blockadeK J Lindley, M J Dunne, C Kane, et al.
Endocrine-Related Cancer|August 23, 2005
Consensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signalling pathways and implications for future treatmentJ M W Gee, A Howell, W J Gullick, et al.
Journal of Molecular Endocrinology|September 29, 2012
Mutations in CUL7, OBSL1 and CCDC8 in 3-M syndrome lead to disordered growth factor signallingD Hanson, P G Murray, T Coulson, et al.
Pageof 9